Nonagen Bioscience announces CE mark for Oncuria® bladd

/PRNewswire/— Nonagen Bioscience, a cancer diagnostics company, today announced CE marking for its Oncuria® immunoassay for bladder cancer. Nonagen Bioscience...

Related Keywords

United States , Charlesj Rosser , Jenny Sparano , Dave Mori , Nonagen Bioscience , Drug Administration , Diagnostic Directive , Public Relations , Health Care Amp Hospitals , Medical Pharmaceuticals , Medical Equipment , Biotechnology , New Products Amp Services ,